2018
Cerebral Embolic Risk During Transcatheter Mitral Valve Interventions An Unaddressed and Unmet Clinical Need?
Pagnesi M, Regazzoli D, Ancona MB, Mangieri A, Lanzillo G, Giannini F, Buzzatti N, Prendergast BD, Kodali S, Lansky AJ, Colombo A, Latib A. Cerebral Embolic Risk During Transcatheter Mitral Valve Interventions An Unaddressed and Unmet Clinical Need? JACC Cardiovascular Interventions 2018, 11: 517-528. PMID: 29566796, DOI: 10.1016/j.jcin.2017.12.018.Peer-Reviewed Original ResearchConceptsTranscatheter mitral valve interventionsCerebral embolic riskMitral valve interventionMV proceduresEmbolic riskValve interventionHeart interventionsProcedure-related adverse eventsPatient-related factorsStructural heart interventionsReal clinical issueMV interventionAdverse eventsEmbolic injuryMV diseaseUnmet ClinicalMV anatomyClinical issuesAvailable evidenceInterventionRiskSystematic assessmentClinicalInjuryAvailable data
2013
TCT-20 Two-Year Clinical Follow-Up of the FIREHAWK Abluminal Groove-Filled Biodegradable Polymer Sirolimus-Eluting Stent in the Treatment of Patients with De Novo Native Coronary Artery Lesions: The TARGET I Trial
Xu B, Gao R, Lansky A, Yang Y, Changsheng M, Han Y, Chen S, Li H, Zhang R, Fu G, Yuan Z, Huo Y, Li W, Zhao Y, Leon M. TCT-20 Two-Year Clinical Follow-Up of the FIREHAWK Abluminal Groove-Filled Biodegradable Polymer Sirolimus-Eluting Stent in the Treatment of Patients with De Novo Native Coronary Artery Lesions: The TARGET I Trial. Journal Of The American College Of Cardiology 2013, 62: b7-b8. DOI: 10.1016/j.jacc.2013.08.748.Peer-Reviewed Original ResearchDe novo native coronary artery lesionsBiodegradable Polymer Sirolimus-Eluting StentNovo native coronary artery lesionsNative coronary artery lesionsCoronary artery lesionsSirolimus-Eluting StentsTreatment of patientsTwo-Year ClinicalAbluminal grooveArtery lesionsI trialPatientsClinicalLesionsStentsTrials
2012
TCT-582 Eighteen Month Clinical and Imaging Results from the DESSOLVE I First-in-Human Trial of the MiStent® SES with Absorbable Polymer
Ormiston J, Stewart J, Webster M, Vrolix M, Whitbourn R, Donohoe D, Knape C, Lansky A, Bezerra H, Fitzgerald P, Kandzari D, Wijns W. TCT-582 Eighteen Month Clinical and Imaging Results from the DESSOLVE I First-in-Human Trial of the MiStent® SES with Absorbable Polymer. Journal Of The American College Of Cardiology 2012, 60: b169. DOI: 10.1016/j.jacc.2012.08.617.Peer-Reviewed Original Research
2011
COMPARISON OF THE PROGNOSTIC UTILITY OF VARIOUS CLINICAL AND ANGIOGRAPHIC RISK SCORES IN PATIENTS WITH ACUTE CORONARY SYNDROMES: ANALYSIS FROM THE ACUITY TRIAL
Palmerini T, Caixeta A, Genereux P, Cristea E, Lansky A, Mehran R, Dangas G, Lazar D, Sanchez R, Corral M, Jankovic I, Fahy M, Xu K, Stone G. COMPARISON OF THE PROGNOSTIC UTILITY OF VARIOUS CLINICAL AND ANGIOGRAPHIC RISK SCORES IN PATIENTS WITH ACUTE CORONARY SYNDROMES: ANALYSIS FROM THE ACUITY TRIAL. Journal Of The American College Of Cardiology 2011, 57: e1106. DOI: 10.1016/s0735-1097(11)61106-6.Peer-Reviewed Original Research
2010
QUANTIFICATION OF AMPLITUDE, SPEED AND COMPLETENESS OF ST-SEGMENT RECOVERY AFTER PRIMARY PERCUTANEOUS CORONARY INTERVENTION FOR ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION: WHAT IS THE “BEST ST” RECOVERY TO PREDICT CLINICAL OUTCOME?
Kuijt W, Roe M, Green C, Verouden N, Haeck J, Tzivoni D, Koch K, Stone G, Lansky A, De Winter R, Krucoff M. QUANTIFICATION OF AMPLITUDE, SPEED AND COMPLETENESS OF ST-SEGMENT RECOVERY AFTER PRIMARY PERCUTANEOUS CORONARY INTERVENTION FOR ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION: WHAT IS THE “BEST ST” RECOVERY TO PREDICT CLINICAL OUTCOME? Journal Of The American College Of Cardiology 2010, 55: a134.e1255. DOI: 10.1016/s0735-1097(10)61256-9.Peer-Reviewed Original Research